1996, ISBN 0921440421, 149
Book
Journal of Chromatography B, ISSN 1570-0232, 06/2017, Volume 1055-1056, pp. 1 - 7
Reversed-phase HPLC with derivatization using -phthalaldehyde (OPA) and sulfite allows electrochemical detection of γ-aminobutyric acid (GABA) in microdialysis...
Sulfite | Fluorescence | GABA | OPA | Microdialysis | HPLC | CHEMISTRY, ANALYTICAL | BIOCHEMICAL RESEARCH METHODS | SULFITE DERIVATIZATION | AMINO-ACID NEUROTRANSMITTERS | PERFORMANCE LIQUID-CHROMATOGRAPHY | BRAIN MICRODIALYSIS | O-PHTHALDIALDEHYDE/3-MERCAPTOPROPIONIC ACID | GLUTAMATE | DOPAMINE | GAMMA-AMINOBUTYRIC-ACID | RAT-BRAIN | L-CYSTEINE REAGENTS | o-Phthalaldehyde - chemistry | Limit of Detection | Animals | Chromatography, High Pressure Liquid - methods | Microdialysis - methods | Rats, Long-Evans | Male | gamma-Aminobutyric Acid - analysis | Corpus Striatum - chemistry | Sulfites - chemistry | Sulfites | Usage | Methods | High performance liquid chromatography | Cysteine | Detectors | Derivatives (Financial instruments) | Electric properties | Borates | Index Medicus | sulfite | microdialysis | fluorescence
Sulfite | Fluorescence | GABA | OPA | Microdialysis | HPLC | CHEMISTRY, ANALYTICAL | BIOCHEMICAL RESEARCH METHODS | SULFITE DERIVATIZATION | AMINO-ACID NEUROTRANSMITTERS | PERFORMANCE LIQUID-CHROMATOGRAPHY | BRAIN MICRODIALYSIS | O-PHTHALDIALDEHYDE/3-MERCAPTOPROPIONIC ACID | GLUTAMATE | DOPAMINE | GAMMA-AMINOBUTYRIC-ACID | RAT-BRAIN | L-CYSTEINE REAGENTS | o-Phthalaldehyde - chemistry | Limit of Detection | Animals | Chromatography, High Pressure Liquid - methods | Microdialysis - methods | Rats, Long-Evans | Male | gamma-Aminobutyric Acid - analysis | Corpus Striatum - chemistry | Sulfites - chemistry | Sulfites | Usage | Methods | High performance liquid chromatography | Cysteine | Detectors | Derivatives (Financial instruments) | Electric properties | Borates | Index Medicus | sulfite | microdialysis | fluorescence
Journal Article
Organometallics, ISSN 0276-7333, 03/1999, Volume 18, Issue 6, pp. 1018 - 1029
The synthesis and characterization of a range of N-alkoxo β-ketoiminate complexes of groups 4 and 5 are reported. Reactions between the acylic N-hydroxyalkyl...
ALKYL DERIVATIVES | ALPHA-OLEFINS | DIELS-ALDER REACTIONS | ZIRCONIUM | TRANSITION-METAL PORPHYRINS | OLEFIN POLYMERIZATION | LIVING POLYMERIZATION | CHEMISTRY, ORGANIC | CRYSTAL-STRUCTURES | CHELATING DIAMIDE COMPLEXES | TITANIUM COMPLEXES | CHEMISTRY, INORGANIC & NUCLEAR
ALKYL DERIVATIVES | ALPHA-OLEFINS | DIELS-ALDER REACTIONS | ZIRCONIUM | TRANSITION-METAL PORPHYRINS | OLEFIN POLYMERIZATION | LIVING POLYMERIZATION | CHEMISTRY, ORGANIC | CRYSTAL-STRUCTURES | CHELATING DIAMIDE COMPLEXES | TITANIUM COMPLEXES | CHEMISTRY, INORGANIC & NUCLEAR
Journal Article
OPTICA, ISSN 2334-2536, 09/2018, Volume 5, Issue 9, pp. 1128 - 1134
Applications of quantum science to computing, cryptography, and imaging are on their way to becoming key next-generation technologies. Owing to the high-speed...
DEFECTS | SILICON | SINGLE-PHOTON EMISSION | OPTICS
DEFECTS | SILICON | SINGLE-PHOTON EMISSION | OPTICS
Journal Article
New Zealand Journal of Marine and Freshwater Research, ISSN 0028-8330, 10/2018, Volume 52, Issue 4, pp. 467 - 486
As Aotearoa New Zealand grapples with developing solutions to complex issues surrounding its unique freshwater and marine biological heritage, there is a...
New Zealand | vision mātauranga | indigenous rights | treaty of waitangi (Te tiriti o waitangi) | sovereignty | Bio-heritage | mātauranga | research | environmental management | Marine biology | Solutions | Inland water environment | Fresh water | Empowerment
New Zealand | vision mātauranga | indigenous rights | treaty of waitangi (Te tiriti o waitangi) | sovereignty | Bio-heritage | mātauranga | research | environmental management | Marine biology | Solutions | Inland water environment | Fresh water | Empowerment
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events...
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article